SENTIA: A systematic online monitoring registry for children and adolescents treated with antipsychotics

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-5

  Palanca Maresca, Inmaculada ^a,f   Ruiz Antorán, Belén ^a   Centeno Soto, Gustavo ^a   Jiménez Fernandez, Sara ^b   García Murillo, Lourdes ^c   Siles, Ana ^a   Villagrá, Sandra ^d   Blasco Fontecilla, Hilario ^a   Iruela Cuadrado, Luis ^a   Roman Riechman, Enriqueta ^a   Avendaño Solá, Cristina ^a   Correll, Christoph U ^e  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f Psychiatry Research ^*  (Spain)

Author keywords

Adolescents; Adverse effects; Antipsychotics; Children; Pharmacovigilance; Registry

Indexed keywords

EID: 84899538880     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-187     Document Type: Article

References (26)

1. Achenbach TM, Edelbrock CS (1981) Behavioral problems and competencies reported by parents of normal and disturbed children aged four through sixteen. Monogr Soc Res Child Dev 46:1-82
2. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL (2005) Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 15:869-884
3. Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4:28-37
4. Correll CU (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47:9-20
5. Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK (2006) Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 15:177-206
6. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773
7. Desmangles JC, Lappe JM, Lipaczewski G, Haynatzki G (2006) Accuracy of pubertal tanner staging self-reporting. J Pediatr Endocrinol Metab 19:213-221
8. Ehlers S, Gillberg C, Wing L (1999) A screening questionnaire for Asperger syndrome and other high-functioning autism spectrum disorders in school age children. J Autism Dev Disord 29:129-141
9. Greenhill LL, Vitiello B, Fisher P, Levine J, Davies M, Abikoff H, Chrisman AK, Chuang S, Findling RL, March J, Scahill L, Walkup J, Riddle MA (2004) Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 43:1488-1496
10. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76-338). US: Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD
11. Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T (2011) Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatr Child Health 16:575-580
12. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M (2007) Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry 16:104-120
13. Lundh A, Kowalski J, Sundberg CJ, Gumpert C, Landen M (2010) Children's Global Assessment Scale (CGAS) in a naturalistic clinical setting: inter-rater reliability and comparison with expert ratings. Psychiatry Res 177:206-210
14. March JS, Silva SG, Compton S, Anthony G, DeVeaugh-Geiss J, Califf R, Krishnan R (2004) The Child and Adolescent Psychiatry Trials Network (CAPTN). J Am Acad Child Adolesc Psychiatry 43:515-518
15. Mehler-Wex C, Kolch M, Kirchheiner J, Antony G, Fegert JM, Gerlach M (2009) Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health 3:14
16. Olfson M, Blanco C, Liu SM, Wang S, Correll CU (2012) National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 69:1247-1256
17. Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH (2010) First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 19:124-137
18. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J (2011) Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health 16:581-589
19. Rani FA, Byrne PJ, Murray ML, Carter P, Wong IC (2009) Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings. Drug Saf 32:325-333
20. Ronsley R, Rayter M, Smith D, Davidson J, Panagiotopoulos C (2012) Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotictreated children. Can J Psychiatry 57:292-299
21. Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, Vandermeer B, Dryden DM, Carrey N (2012) Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 129:e771-e784
22. Shapiro M, Silva SG, Compton S, Chrisman A, DeVeaugh-Geiss J, Breland-Noble A, Kondo D, Kirchner J, March JS (2009) The child and adolescent psychiatry trials network (CAPTN): infrastructure development and lessons learned. Child Adolesc Psychiatry Ment Health 3:12
23. Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers JE, Milo KM, Stock SL, Wilkinson B (2010) Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). J Clin Psychiatry 71:313-326
24. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19
25. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C (2009) Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19:629-635
26. Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 21:600-620